Published in Antimicrob Agents Chemother on June 01, 1991
Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev (1996) 1.85
Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J (2012) 1.53
Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob Agents Chemother (1992) 1.52
Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob Agents Chemother (1992) 1.50
Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother (1995) 1.48
Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother (1994) 1.20
Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother (1992) 1.14
Tissue penetration of antifungal agents. Clin Microbiol Rev (2014) 1.13
Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother (1995) 0.87
In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus. Antimicrob Agents Chemother (1999) 0.84
Scaling basic toxicokinetic parameters from rat to man. Environ Health Perspect (1996) 0.83
Comparative toxicities and pharmacokinetics of intrathecal lipid (amphotericin B colloidal dispersion) and conventional deoxycholate formulations of amphotericin B in rabbits. Antimicrob Agents Chemother (2001) 0.83
Comparative neurotoxicities of amphotericin B and its mono-methyl ester derivative in rats. Antimicrob Agents Chemother (1993) 0.80
Safety of amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis (1997) 0.80
An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis. Int J Nanomedicine (2014) 0.79
Pharmacokinetics of amphotericin B colloidal dispersion in critically ill patients with cholestatic liver disease. Antimicrob Agents Chemother (2012) 0.75
In search of the amazing technicolour dream coat for amphotericin B. Can J Infect Dis (1996) 0.75
Protein-functionalized PLGA nanoparticles of lamotrigine for neuropathic pain management. AAPS PharmSciTech (2014) 0.75
An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis. Parasitol Res (2016) 0.75
Amphotericin B: 30 years of clinical experience. Rev Infect Dis (1990) 5.82
A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis (1969) 5.58
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis (1982) 2.36
Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis (1984) 1.93
Amphotericin B: delivery systems. Antimicrob Agents Chemother (1990) 1.78
Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis (1982) 1.77
Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv (1984) 1.74
Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J Infect Dis (1990) 1.46
In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B. Infect Immun (1990) 1.42
Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol (1988) 1.38
Antifungal agents used in systemic mycoses. Activity and therapeutic use. Drugs (1983) 1.35
Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother (1984) 1.31
The role of liposomal amphotericin B in the treatment of systemic fungal infections. Eur J Cancer Clin Oncol (1989) 1.07
Amphotericin B. Still the 'gold standard' for antifungal therapy. Postgrad Med (1990) 0.97
Involvement of host macrophages in the immunoadjuvant activity of amphotericin B in a mouse fungal infection model. J Antibiot (Tokyo) (1986) 0.93
Solubility and stability of amphotericin B in human serum. Ther Drug Monit (1989) 0.89
Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B. Indian J Biochem Biophys (1989) 0.86
Differential properties of organ-specific serum opsonins for liver and spleen macrophages. Biochim Biophys Acta (1989) 0.83
Effect of blood sampling schedules on protein drug binding in the rat. J Pharmacol Exp Ther (1981) 0.81
Hypocholesterolemic effect of amphotericin B: an analytical approach. Res Commun Chem Pathol Pharmacol (1974) 0.81
Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J (2001) 8.90
Quenching quorum-sensing-dependent bacterial infection by an N-acyl homoserine lactonase. Nature (2001) 4.73
Structural insights into the evolution of an antibody combining site. Science (1997) 3.92
Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell (1999) 3.84
Location of envelope-specific and sarcoma-specific oligonucleotides on RNA of Schmidt-Ruppin Rous sarcoma virus. Proc Natl Acad Sci U S A (1976) 3.73
Recombination between viral and cellular sequences generates transforming sarcoma virus. Proc Natl Acad Sci U S A (1978) 3.38
Properties and location of poly(A) in Rous sarcoma virus RNA. J Virol (1974) 3.22
Addiction rare in patients treated with narcotics. N Engl J Med (1980) 3.20
Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science (2001) 2.98
Nucleotide sequence of avian sarcoma virus UR2 and comparison of its transforming gene with other members of the tyrosine protein kinase oncogene family. J Virol (1985) 2.88
Tuberculosis and HIV infection. Lancet (1993) 2.75
Characterization of the transforming gene of Fujinami sarcoma virus. Proc Natl Acad Sci U S A (1980) 2.68
RNA of replication-defective strains of Rous sarcoma virus. Proc Natl Acad Sci U S A (1975) 2.37
Distribution of envelope-specific and sarcoma-specific nucleotide sequences from different parents in the RNAs of avian tumor virus recombinants. Proc Natl Acad Sci U S A (1976) 2.32
Carcinogenic epoxides of benzo[a]pyrene and cyclopenta[cd]pyrene induce base substitutions via specific transversions. Proc Natl Acad Sci U S A (1982) 2.29
Higher risk of preterm birth and low birth weight in women with periodontal disease. J Dent Res (2002) 2.25
Avian sarcoma virus UR2 encodes a transforming protein which is associated with a unique protein kinase activity. J Virol (1982) 2.14
Reproducible high yield of rat islets by stationary in vitro digestion following pancreatic ductal or portal venous collagenase injection. Transplantation (1987) 2.14
Prevalence of Pasteurella haemolytica in transported calves. Am J Vet Res (1983) 2.08
Relation between smoking and age of natural menopause. Report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. Lancet (1977) 2.00
The structurally distinct form of pp60c-src detected in neuronal cells is encoded by a unique c-src mRNA. Mol Cell Biol (1987) 1.98
Evaluation of a new rapid bacteriophage-based method for the drug susceptibility testing of Mycobacterium tuberculosis. Nat Med (1997) 1.95
Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule. Mol Cell Biol (1986) 1.89
DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J Clin Invest (2001) 1.89
Proto-oncogene c-ros codes for a molecule with structural features common to those of growth factor receptors and displays tissue specific and developmentally regulated expression. Mol Cell Biol (1986) 1.88
Thiacetazone--avoid like poison or use with care? Trans R Soc Trop Med Hyg (1994) 1.88
Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res (2000) 1.86
Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem (2000) 1.82
Isoprotein specificity in the hepatic uptake of apolipoprotein E and the pathogenesis of familial dysbetalipoproteinemia. Proc Natl Acad Sci U S A (1980) 1.79
Reactions of normal and leukemic cell surfaces to a wheat germ agglutinin. Proc Natl Acad Sci U S A (1965) 1.75
DNA polymerase of murine sarcoma-leukemia virus: lack of detectable RNase H and low activity with viral RNA and natural DNA templates. J Virol (1973) 1.73
The gene order of avian RNA tumor viruses derived from biochemical analyses of deletion mutants and viral recombinants. Annu Rev Microbiol (1978) 1.72
HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users. Lancet (1990) 1.70
The terminal oligonucleotides of avian tumor virus RNAs are genetically linked. Virology (1977) 1.70
Unilamellar liposomes made with the French pressure cell: a simple preparative and semiquantitative technique. J Lipid Res (1980) 1.64
Managing tuberculosis and HIV infection. BMJ (1992) 1.56
Drug-related deaths among medical inpatients. JAMA (1977) 1.53
The COUP transcription factor binds to an upstream promoter element of the rat insulin II gene. Mol Cell Biol (1988) 1.53
Randomized comparison of routine vs highly selective use of Doppler ultrasound and biophysical scoring to investigate high risk pregnancies. Br J Obstet Gynaecol (1990) 1.52
Risk and the general practitioner budget holder. Soc Sci Med (1998) 1.52
Capitation and risk adjustment in health care financing: an international progress report. Milbank Q (2001) 1.52
Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med (1994) 1.50
A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI) J Rheumatol (1995) 1.49
High percentage inorganic arsenic content of mining impacted and nonimpacted Chinese rice. Environ Sci Technol (2008) 1.48
Phosphatidylinositol kinase type I activity associates with various oncogene products. Oncogene Res (1989) 1.48
Relative analgesia. An evaluation of the efficacy and safety. Br Dent J (1979) 1.48
Src kinases involved in hepatitis B virus replication. EMBO J (1999) 1.47
Drug-induced gastrointestinal bleeding. Report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. Lancet (1978) 1.45
Screening for prolonged incubation of HTLV-I infection in British and Jamaican relatives of British patients with tropical spastic paraparesis. BMJ (1990) 1.45
Self-Assembled Metal Colloid Monolayers: An Approach to SERS Substrates. Science (1995) 1.45
Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun (1994) 1.44
Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding. J Exp Med (1990) 1.44
Mechanism of STAT3 activation by insulin-like growth factor I receptor. J Biol Chem (2000) 1.42
Genetic structure and transforming sequence of avian sarcoma virus UR2. J Virol (1982) 1.42
Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther (1996) 1.41
Practice guidelines: lower extremity revascularization. J Vasc Surg (1993) 1.41
Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev (2001) 1.41
Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol Cell Biol (2000) 1.40
Internal mammary artery for arterial pressure monitoring after pediatric cardiac operations. Ann Thorac Surg (1993) 1.39
Relationships between static histomorphometry and ultrasound in the human calcaneus. Calcif Tissue Int (1999) 1.39
Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Natl Acad Sci U S A (1992) 1.38
The origin of 47,XXY and 47,XXX aneuploidy: heterogeneous mechanisms and role of aberrant recombination. Hum Mol Genet (1994) 1.36
Molecular cloning and characterization of avian sarcoma virus UR2 and comparison of its transforming sequence with those of other avian sarcoma viruses. J Virol (1984) 1.36
Effects of air pollution on adult pulmonary function. Arch Environ Health (1991) 1.35
Evidence of early ovarian aging in fragile X premutation carriers. J Clin Endocrinol Metab (2004) 1.35
Genetic structure, transforming sequence, and gene product of avian sarcoma virus UR1. J Virol (1981) 1.35
Emergence of vancomycin-resistant enterococci at a university hospital in Taiwan: persistence of multiple species and multiple clones. Infect Control Hosp Epidemiol (1999) 1.34
Interactions of the vnd/NK-2 homeodomain with DNA by nuclear magnetic resonance spectroscopy: basis of binding specificity. Biochemistry (1997) 1.34
Drug-induced anaphylaxis, convulsions, deafness, and extrapyramidal symptoms. Lancet (1977) 1.33
Patterns of cytopathology and lysosomal enzyme release in poliovirus-infected HEp-2 cells treated with either 2-(alpha-hydroxybenzyl)-benzimidazole or guanidine HCl. J Gen Virol (1970) 1.32
Molecular cloning of the Fujinami sarcoma virus genome and its comparison with sequences of other related transforming viruses. J Virol (1982) 1.28
India's Revised National Tuberculosis Control Programme: looking beyond detection and cure. Int J Tuberc Lung Dis (2008) 1.24
Comparison of hydroperoxide initiator requirements for the cyclooxygenase activities of prostaglandin H synthase-1 and -2. J Biol Chem (1995) 1.23
League tables for performance improvement in health care. J Health Serv Res Policy (1998) 1.23
Apolipoprotein E localization in rat hepatocytes by immunogold labeling of cryothin sections. J Lipid Res (1990) 1.23
Mechanisms of receptor-mediated transmembrane communication. Cold Spring Harb Symp Quant Biol (1986) 1.22
Prognostic indicators in venous ulcers. J Am Acad Dermatol (2000) 1.22
Healthcare-associated outbreak due to pan-drug resistant Acinetobacter baumannii in a surgical intensive care unit. J Hosp Infect (2003) 1.21
Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother (2001) 1.20
Evidence for insulin-dependent activation of S6 and microtubule-associated protein-2 kinases via a human insulin receptor/v-ros hybrid. J Biol Chem (1990) 1.19
Assessing the performance of NHS hospital trusts: the role of 'hard' and 'soft' information. Health Policy (1999) 1.19
Visual benefit of correcting higher order aberrations of the eye. J Refract Surg (2001) 1.18
Evidence for the common origin of viral and cellular sequences involved in sarcomagenic transformation. J Virol (1980) 1.17
Analysis of the src gene of sarcoma viruses generated by recombination between transformation-defective mutants and quail cellular sequences. J Virol (1979) 1.17
Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and definition of cellular immune responses. Eur J Clin Nutr (2000) 1.16
Purification and some properties of an extracellular maltase from Bacillus subtilis. Appl Environ Microbiol (1976) 1.15
New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro. J Med Chem (1986) 1.15
Growth and gene expression are predominantly controlled by distinct regions of the human IL-4 receptor. Immunity (1996) 1.15
Phosphorylase b kinase inheritance in mice. Science (1967) 1.14
Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother (1992) 1.14
ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Oncogene (2001) 1.14
Interferon-gamma and interleukin-2 release by lymphocytes derived from the blood, mesenteric lymph nodes and intestines of normal sheep and those affected with paratuberculosis (Johne's disease). Vet Immunol Immunopathol (1999) 1.13
Decreased striatal D2 dopamine receptors in obese Zucker rats: changes during aging. Brain Res (1992) 1.13
Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method. J Hepatol (2000) 1.13
A study of immunological responses of sheep clinically-affected with paratuberculosis (Johne's disease). The relationship of blood, mesenteric lymph node and intestinal lymphocyte responses to gross and microscopic pathology. Vet Immunol Immunopathol (1998) 1.12
Chlamydial polyarthritis of lambs: a review. J Am Vet Med Assoc (1972) 1.11
Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem (1999) 1.11
Distinct role of phosphatidylinositol 3-kinase and Rho family GTPases in Vav3-induced cell transformation, cell motility, and morphological changes. J Biol Chem (2002) 1.10